When an FDA inspector raised questions about water streaming down some equipment in the fill-and-finish area at Dr. Reddy’s oncology plant in Duvvada, India, a quality control manager repeatedly waved it off as condensation. When the inspector pointed out it was flowing from a tube that someone had tried to fix with three zip ties and was a problem in a sterile area, the manager finally acquiesced and stopped the filling line.
Facing claims it induced doctors to prescribe a generic version of GlaxoSmithKline’s Coreg that violated its patents, Teva was hit with a hefty $235 million penalty in 2017. But a federal judge overruled that jury’s verdict last year—and now, one (US) federal appeals judge says she's “baffled" by the decision.
In recognition of their outstanding contributions to the Pharmacy profession, Pharmaceutical industry and support to the National Agency for Food and Drug, Administration and Control (NAFDAC) in ensuring access to safe, efficacious and affordable medicines in Nigeria, the President, Nigeria Academy of Pharmacy (NAPharm) Prince Julius Adelusi-Adeluyi, and the Immediate Past President (IPP) of the Pharmaceutical Society of Nigeria (PSN) Pharm. Ahmed I Yakasai, have been decorated with Legacy Award by NAFDAC.
Less than 48 hours before the first major opioid trial began, Teva struck an $85 million deal with Oklahoma officials, about one-third what painkiller giant Purdue Pharma paid to settle similar claims. The settlement resolves claims that its painkillers—and their marketing—fed an opioid addiction crisis in Oklahoma. Teva didn't admit any wrongdoing with its settlement.